MRK · Merck & Co., Inc.
$128.382026-07-21Sector: Healthcare; Industry: Drug Manufacturers - General; Sub-Industry: Pharmaceuticals
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Very High Uncertainty
Bull
$515
+301.1% vs market
Base · active
$122
-5.1% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($114 · $515) Analysts Range ($100 · $150) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2024.Q1 | $60.1B | — | 4.9% | 40.7% | $1.8B | $3.7B | $5.4B | 5.2% | — | 0.9% | $205.5B | $0.15 | — |
| 2024.Q4 | $60.1B | 0.0% | 4.9% | 14.1% | $2.5B | $10.1B | $12.7B | 5.7% | — | 1.2% | $206.5B | $0.15 | — |
| 2025.Q1 | $64.2B | 6.7% | 31.5% | 13.5% | $17.5B | $3.3B | $20.8B | 5.4% | — | 9.7% | $154.1B | $6.92 | — |
| 2025.Q4 | $64.2B | 0.0% | 31.5% | 13.3% | $17.5B | −$5.4B | $12.1B | 5.4% | — | 10.9% | $167.9B | $6.92 | — |
| 2026.Q1 | $65.6B | 2.2% | 27.6% | 23.2% | $13.9B | −$9.1B | $4.8B | 5.1% | — | 8.9% | $145.2B | $3.61 | 17.5 |
| italics below = DCF projection · 10yr Rev CAGR: 4.5% |
| 2027.Q1 | $67.6B | +3.0% | 36.2% | 22.9% | $18.9B | −$8.9B | $10.0B | 5.4% | $9.4B | 12.6% | $154.2B | $7.64 | 16.8 |
| 2028.Q1 | $71.4B | +5.7% | 52.2% | 22.6% | $28.9B | −$12.9B | $16.0B | 5.8% | $14.3B | 18.0% | $167.0B | $11.67 | 11.0 |
| 2029.Q1 | $75.0B | +5.0% | 49.9% | 22.2% | $29.1B | −$9.6B | $19.5B | 6.1% | $16.5B | 16.9% | $176.6B | $11.77 | 10.9 |
| 2030.Q1 | $78.7B | +4.9% | 53.5% | 21.9% | $32.9B | −$15.1B | $17.7B | 6.4% | $14.1B | 17.8% | $191.8B | $13.30 | 9.7 |
| 2031.Q1 | $82.4B | +4.8% | 53.5% | 21.6% | $34.6B | −$14.9B | $19.6B | 6.7% | $14.6B | 17.4% | $206.7B | $13.99 | 9.2 |
|
| Term. Yr+ | $106.3B | 4.1% | 30.5% | 20.0% | $25.9B | −$11.2B | $14.7B | 8.6% | $168.2B | 9.5% | — | — | — |
Active scenario IV: $122 (-5.1% vs market)